Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

971 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Novel Delivery Systems for Checkpoint Inhibitors.
Lamichhane P, Deshmukh R, Brown JA, Jakubski S, Parajuli P, Nolan T, Raja D, Badawy M, Yoon T, Zmiyiwsky M, Lamichhane N. Lamichhane P, et al. Among authors: nolan t. Medicines (Basel). 2019 Jul 11;6(3):74. doi: 10.3390/medicines6030074. Medicines (Basel). 2019. PMID: 31373327 Free PMC article. Review.
mRNA vaccines encoding membrane-anchored RBDs of SARS-CoV-2 mutants induce strong humoral responses and can overcome immune imprinting.
Al-Wassiti HA, Fabb SA, Grimley SL, Kochappan R, Ho JK, Wong CY, Tan CW, Payne TJ, Takanashi A, Lee CL, Mugan RS, Sicilia H, Teo SLY, McAuley J, Ellenberg P, Cooney JP, Davidson KC, Bowen R, Pellegrini M, Rockman S, Godfrey DI, Nolan TM, Wang LF, Deliyannis G, Purcell DFJ, Pouton CW. Al-Wassiti HA, et al. Among authors: nolan tm. Mol Ther Methods Clin Dev. 2024 Nov 15;32(4):101380. doi: 10.1016/j.omtm.2024.101380. eCollection 2024 Dec 12. Mol Ther Methods Clin Dev. 2024. PMID: 39687732 Free PMC article.
Breadth of immune response, immunogenicity, reactogenicity, and safety for a pentavalent meningococcal ABCWY vaccine in healthy adolescents and young adults: results from a phase 3, randomised, controlled observer-blinded trial.
Nolan T, Bhusal C, Beran J, Bloch M, Cetin BS, Dinleyici EC, Dražan D, Kokko S, Koski S, Laajalahti O, Langley JM, Rämet M, Richmond PC, Silas P, Tapiero B, Tiong F, Tipton M, Ukkonen B, Ulukol B, Lattanzi M, Trapani M, Willemsen A, Toneatto D; QUINTET study group. Nolan T, et al. Lancet Infect Dis. 2024 Dec 5:S1473-3099(24)00667-4. doi: 10.1016/S1473-3099(24)00667-4. Online ahead of print. Lancet Infect Dis. 2024. PMID: 39647494
4CMenB Breadth of Immune Response, Immunogenicity, and Safety: Results From a Phase 3 Randomized, Controlled, Observer Blind Study in Adolescents and Young Adults.
Nolan T, Bhusal C, Beran J, Bloch M, Cetin BS, Dinleyici EC, Dražan D, Kokko S, Koski S, Laajalahti O, Langley JM, Rämet M, Richmond PC, Silas P, Tapiero B, Tiong F, Tipton M, Ukkonen B, Ulukol B, Lattanzi M, Trapani M, Willemsen A, Toneatto D; QUINTET study group. Nolan T, et al. Open Forum Infect Dis. 2024 Oct 30;11(11):ofae638. doi: 10.1093/ofid/ofae638. eCollection 2024 Nov. Open Forum Infect Dis. 2024. PMID: 39582508 Free PMC article. Clinical Trial.
971 results